Clinical Trial Update: Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating nab-paclitaxel in ER+/HER2- recurrent metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN